UGT1A9 Lentiviral Activation Particles (h): sc-417693-LAC

Human UGT1A9 encodes UDP‑glucuronosyltransferase 1A9, an endoplasmic reticulum–associated phase II metabolism enzyme that conjugates glucuronic acid to diverse xenobiotics and endogenous substrates to increase solubility and promote clearance. It functions within hepatic and extrahepatic glucuronidation networks that shape cellular exposure to small molecules and influence downstream oxidative stress and inflammatory signaling. Variation in UGT1A9 expression or activity is linked to interindividual differences in drug disposition and susceptibility to adverse responses, and has been explored in contexts such as liver function, renal handling of metabolites, and cancer pharmacology. As a key determinant of conjugative metabolism, UGT1A9 is widely used to study detoxification capacity, pathway crosstalk with transporters, and regulation by nuclear receptors.

UGT1A9 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient UGT1A9 upregulation across a broader range of human cell types.

UGT1A9 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the UGT1A9 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous UGT1A9 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native UGT1A9 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.